Vol 73, No 5 (2022)
Review paper
Published online: 2022-10-06

open access

Page views 5043
Article views/downloads 2636
Get Citation

Connect on Social Media

Connect on Social Media

The content of this article is also available in the following languages:
English

Liquid levothyroxine improves thyroid control in patients with different hypothyroidism aetiology and variable adherence — case series and review

Marek Ruchała1, Artur Bossowski2, Magdalena M. Brzozka3, Małgorzata Gietka-Czernel4, Alicja Hubalewska-Dydejczyk5, Beata Kos-Kudła6, Andrzej Lewiński7, Anhelli Syrenicz8, Wojcech Zgliczyński4
Pubmed: 36621916
Endokrynol Pol 2022;73(5):893-902.

Abstract

It is estimated that hypothyroidism treatment may be either suboptimal or excessive in about 32–45% patients treated with L-thyroxine (LT4). There are multiple possible causes of poor control of hypothyroidism, including narrow LT4 therapeutic index, food and drug interactions, comorbidities, and patient non-adherence. Some of these obstacles could possibly be overcome with the novel liquid LT4 formulation. Liquid LT4 reaches maximum blood concentration about 30 minutes faster than the tablet form. Faster pharmacokinetics might lead to more efficient LT4 absorption, as suggested by a recent real-world study in patients with primary and central hypothyroidism.

Liquid LT4 treatment led to increased free thyroxine (FT4) and sex hormone binding globulin (SHBG) with decreased low-density lipoprotein (LDL) cholesterol concentration and substantially improved quality of life for the patients. Herein we present a series of 31 patients with hypothyroidism of different aetiologies treated with the novel liquid LT4 formulation in standard clinical care in light of the latest scientific publications on liquid LT4 formula. We observed normalization of thyroid function tests shortly after introduction of liquid LT4, irrespective of concurrent diseases or concomitant medications that could diminish LT4 absorption. In more detail, the treatment with liquid LT4 managed to normalize thyroid-stimulating hormone (TSH) concentrations in patients without any known causes of LT4 absorption disturbances, as well as in those with malabsorption: with gastric bypass, partial small and large intestine resection, scleroderma, gluten intolerance, celiac disease, atrophic gastritis, and polytherapy. In conclusion, considering many factors disturbing
LT4 absorption, hypothyroidism therapy with liquid LT4 seems to be a particularly effective option.

 

Article available in PDF format

View PDF (Polish) Download PDF file

References

  1. Garmendia Madariaga A, Santos Palacios S, Guillén-Grima F, et al. The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J Clin Endocrinol Metab. 2014; 99(3): 923–931.
  2. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002; 87(2): 489–499.
  3. Centanni M, Benvenga S, Sachmechi I. Diagnosis and management of treatment-refractory hypothyroidism: an expert consensus report. J Endocrinol Invest. 2017; 40(12): 1289–1301.
  4. Peterson SJ, Cappola AR, Castro MR, et al. An Online Survey of Hypothyroid Patients Demonstrates Prominent Dissatisfaction. Thyroid. 2018; 28(6): 707–721.
  5. Mitchell AL, Hegedüs L, Žarković M, et al. Patient satisfaction and quality of life in hypothyroidism: An online survey by the british thyroid foundation. Clin Endocrinol (Oxf). 2021; 94(3): 513–520.
  6. Hegedüs L, Bianco AC, Jonklaas J, et al. Primary hypothyroidism and quality of life. Nat Rev Endocrinol. 2022; 18(4): 230–242.
  7. Virili C, Antonelli A, Santaguida MG, et al. Gastrointestinal Malabsorption of Thyroxine. Endocr Rev. 2019; 40(1): 118–136.
  8. Jonklaas J, Bianco AC, Bauer AJ, et al. American Thyroid Association Task Force on Thyroid Hormone Replacement. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 2014; 24(12): 1670–1751.
  9. Pearce SHS, Brabant G, Duntas LH, et al. 2013 ETA Guideline: Management of Subclinical Hypothyroidism. Eur Thyroid J. 2013; 2(4): 215–228.
  10. Castellana M, Castellana C, Giovanella L, et al. Prevalence of gastrointestinal disorders having an impact on tablet levothyroxine absorption: should this formulation still be considered as the first-line therapy? Endocrine. 2020; 67(2): 281–290.
  11. McMillan M, Rotenberg KS, Vora K, et al. Comorbidities, Concomitant Medications, and Diet as Factors Affecting Levothyroxine Therapy: Results of the CONTROL Surveillance Project. Drugs R D. 2016; 16(1): 53–68.
  12. Yue CS, Scarsi C, Ducharme MP. Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms. Arzneimittelforschung. 2012; 62(12): 631–636.
  13. Ducharme M, Scarsi C, Bettazzi E, et al. A Novel Levothyroxine Solution Results in Similar Bioavailability Whether Taken 30 or Just 15 Minutes Before a High-Fat High-Calorie Meal. Thyroid. 2022; 32(8): 897–904.
  14. Bornikowska K, Gietka-Czernel M, Raczkiewicz D, et al. Improvements in Quality of Life and Thyroid Parameters in Hypothyroid Patients on Ethanol-Free Formula of Liquid Levothyroxine Therapy in Comparison to Tablet LT4 Form: An Observational Study. J Clin Med. 2021; 10(22).
  15. Jarząb B, Dedecjus M, Lewiński A, et al. Diagnosis and treatment of thyroid cancer in adult patients - Recommendations of Polish Scientific Societies and the National Oncological Strategy. 2022 Update [Diagnostyka i leczenie raka tarczycy u chorych dorosłych - Rekomendacje Polskich Towarzystw Naukowych oraz Narodowej Strategii Onkologicznej. Aktualizacja na rok 2022]. Endokrynol Pol. 2022; 73(2): 173–300.
  16. Hubalewska-Dydejczyk A, Trofimiuk-Müldner M, Ruchala M, et al. Thyroid diseases in pregnancy: guidelines of the Polish Society of Endocrinology [Choroby tarczycy w ciąży: zalecenia postępowania Polskiego Towarzystwa Endokrynologicznego]. Endokrynol Pol. 2021; 72(5): 425–488.
  17. Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017; 27(3): 315–389.
  18. Fallahi P, Ferrari SM, Antonelli A. Oral L-thyroxine liquid versus tablet in patients with hypothyroidism without malabsorption: a prospective study. Endocrine. 2016; 52(3): 597–601.
  19. Fallahi P, Ferrari SM, Camastra S, et al. TSH Normalization in Bariatric Surgery Patients After the Switch from L-Thyroxine in Tablet to an Oral Liquid Formulation. Obes Surg. 2017; 27(1): 78–82.
  20. Benvenga S, Di Bari F, Vita R. Undertreated hypothyroidism due to calcium or iron supplementation corrected by oral liquid levothyroxine. Endocrine. 2017; 56(1): 138–145.
  21. Vita R, Saraceno G, Trimarchi F, et al. Switching levothyroxine from the tablet to the oral solution formulation corrects the impaired absorption of levothyroxine induced by proton-pump inhibitors. J Clin Endocrinol Metab. 2014; 99(12): 4481–4486.
  22. Brancato D, Scorsone A, Saura G, et al. Comparison of TSH Levels with Liquid Formulation Versus Tablet Formulations of Levothyroxine in the Treatment of Adult Hypothyroidism. Endocr Pract. 2014; 20(7): 657–662.
  23. Vita R, Di Bari F, Benvenga S. Oral liquid levothyroxine solves the problem of tablet levothyroxine malabsorption due to concomitant intake of multiple drugs. Expert Opin Drug Deliv. 2017; 14(4): 467–472.
  24. Virili C, Giovanella L, Fallahi P, et al. Levothyroxine Therapy: Changes of TSH Levels by Switching Patients from Tablet to Liquid Formulation. A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne). 2018; 9: 10.
  25. Laurent I, Tang S, Astère M, et al. Liquid L-thyroxine versus tablet L-thyroxine in patients on L- thyroxine replacement or suppressive therapy: a meta-analysis. Endocrine. 2018; 61(1): 28–35.
  26. Ruchała M, Szczepanek-Parulska E, Zybek A. The influence of lactose intolerance and other gastro-intestinal tract disorders on L-thyroxine absorption. Endokrynol Pol. 2012; 63(4): 318–323.
  27. Bellastella G, Caputo M, Maiorino MI, et al. EMPATHY: A New Tool for Identifying the Most Suitable Thyroxine Formulation in Hypothyroid Patients. Thyroid. 2019; 29(7): 928–933.
  28. Trimboli P, Scappaticcio L, De Bellis A, et al. Different Formulations of Levothyroxine for Treating Hypothyroidism: A Real-Life Study. Int J Endocrinol. 2020; 2020: 4524759.
  29. Virili C, Trimboli P, Romanelli F, et al. Liquid and softgel levothyroxine use in clinical practice: state of the art. Endocrine. 2016; 54(1): 3–14.
  30. Bednarczuk T, Attanasio R, Hegedüs L, et al. Use of thyroid hormones in hypothyroid and euthyroid patients: a THESIS* questionnaire survey of Polish physicians. *THESIS: Treatment of hypothyroidism in Europe by specialists: an international survey. Endokrynol Pol. 2021; 72(4): 357–365.
  31. Sawicka-Gutaj N, Watt T, Sowiński J, et al. ThyPROpl — The Polish version of the thyroid-specific quality of life questionnaire ThyPRO. Endokrynol Pol. 2015; 66(4): 367–380.
  32. Cappelli C, Negro R, Pirola I, et al. Levothyroxine liquid solution versus tablet form for replacement treatment in pregnant women. Gynecol Endocrinol. 2016; 32(4): 290–292.
  33. Kucharska AM, Beń-Skowronek I, Walczak M, et al. Congenital hypothyroidism - Polish recommendations for therapy, treatment monitoring, and screening tests in special categories of neonates with increased risk of hypothyroidism. Endokrynol Pol. 2016; 67(5): 536–547.
  34. Meyer LM, Stephens K, Carter CA, et al. Stability and consistency of compounded oral liquid levothyroxine formulations. J Am Pharm Assoc (2003). 2020; 60(6): e168–e172.
  35. Peroni E, Vigone MC, Mora S, et al. Congenital hypothyroidism treatment in infants: a comparative study between liquid and tablet formulations of levothyroxine. Horm Res Paediatr. 2014; 81(1): 50–54.
  36. Cassio A, Monti S, Rizzello A, et al. Comparison between liquid and tablet formulations of levothyroxine in the initial treatment of congenital hypothyroidism. J Pediatr. 2013; 162(6): 1264–9, 1269.e1.
  37. Feldt MM. Delayed Diagnosis of Congenital Hypothyroidism in a Child with Trisomy 21 and Biotinidase Deficiency and Successful Use of Levothyroxine Sodium Oral Solution. Case Rep Endocrinol. 2020; 2020: 8883969.
  38. Asamoah E. Levothyroxine sodium oral solution to control thyroid function in a patient with hypothyroidism and celiac disease. Clin Case Rep. 2021; 9(5): e04170.
  39. Ruchała M. Increased efficacy of hypothyroidism control with liquid levothyroxine [Większa skuteczność lewotyroksyny w postaci płynnej w wyrównywaniu niedoczynności tarczycy]. Endokrynol Pol. 2021; 72(3): 271–275.
  40. Bohinc Henderson B. Levothyroxine Sodium Oral Solution Normalizes Thyroid Function in a Patient with Hashimoto's Disease, Gastritis, Diabetic Gastroparesis, and Small Intestinal Bacterial Overgrowth (SIBO). Int Med Case Rep J. 2021; 14: 627–632.